The combination of YAP1 inhibition with oxidative phosphorylation inhibitors significantly reduced the viability of several soft tissue sarcoma cell lines, suggesting a promising therapeutic approach.The transcriptional co-analysis of the study shows that YAP1- and KRAS-driven sarcomas may represent a continuum of sarcoma subtypes. Here, KRAS is linked to sarcoma.